3.8 Article

PCSK9 monoclonal antibodies: An overview

Journal

HEART VIEWS
Volume 21, Issue 2, Pages 97-103

Publisher

WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/HEARTVIEWS.HEARTVIEWS_20_20

Keywords

Alirocumab; antidrug antibody; bococizumab; cardiovascular diseases; evolocumab; familial hypercholesterolemia; neurocognitive; proprotein convertase subtilisin-kexin type 9 inhibitors

Ask authors/readers for more resources

PCSK9 monoclonal antibodies are novel lipid-lowering therapy that have been extensively studied in patients with hypercholesterolemia either as monotherapy or as an add-on to other LLTs. PCSK9 monoclonal antibodies have significantly reduced the low-density lipoprotein cholesterol (LDL-C) plasma level resulting in a better LDL-C goal attainment. The commercially available PCSK9 monoclonal antibodies, alirocumab and evolocumab, have demonstrated reductions in major adverse cardiovascular events such as myocardial infarction, stroke, unstable angina, and the need for coronary revascularization but not mortality. PCSK9 monoclonal antibodies have demonstrated a favorable safety profile. The most reported side effects are mild injection site with no causal relationship proven between the inhibition of PCSK9 and neurocognitive or glycemic adverse events. In this overview, the efficacy and safety of PCSK9 monoclonal antibodies in the treatment of primary and familial hypercholesterolemia will be discussed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available